Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.650
+0.090 (3.52%)
At close: Sep 26, 2025, 4:00 PM EDT
2.640
-0.010 (-0.38%)
After-hours: Sep 26, 2025, 7:40 PM EDT
Esperion Therapeutics Employees
Esperion Therapeutics had 304 employees as of December 31, 2024. The number of employees increased by 64 or 26.67% compared to the previous year.
Employees
304
Change (1Y)
64
Growth (1Y)
26.67%
Revenue / Employee
$881,990
Profits / Employee
-$342,178
Market Cap
534.30M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ESPR News
- 8 days ago - Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia - GlobeNewsWire
- 20 days ago - Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 22 days ago - Top 2 Health Care Stocks That May Plunge This Month - Benzinga
- 4 weeks ago - Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias - GlobeNewsWire
- 7 weeks ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Esperion to Report Second Quarter 2025 Financial Results on August 5 - GlobeNewsWire